Aralez Pharma (ARLZ) Misses Q1 EPS by 4c

Aralez Pharma (NASDAQ: ARLZ) reported Q1 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $31 million.

For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c